Search

Arcus Biosciences Inc

Suletud

SektorTervishoid

27.73 -1.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.74

Max

28.5

Põhinäitajad

By Trading Economics

Sissetulek

-22M

-128M

Müük

-16M

17M

Aktsiakasum

-1.02

Kasumimarginaal

-752.941

Töötajad

601

EBITDA

-42M

-123M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+29.72% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. aug 2026

Turustatistika

By TradingEconomics

Turukapital

258M

3.5B

Eelmine avamishind

29.22

Eelmine sulgemishind

27.73

Uudiste sentiment

By Acuity

23%

77%

62 / 342 Pingereas Healthcare

Arcus Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. juuli 2026, 23:46 UTC

News

PayPal Holdings Inc. shares are lower in after-market trading despite expanding buy now, pay later options in the UK with a new Pay in 30 Days feature.

14. juuli 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

14. juuli 2026, 23:32 UTC

Social Media
News

Advanced Micro Devices shares rose in after-market hours following price target increases by analysts, including KeyBanc's $725 target amid strong demand for EPYC processors.

14. juuli 2026, 23:32 UTC

News
Social Media

Micron Technology's stock rose in after-market trading following a lower-than-expected inflation report and positive sentiment from IBM regarding memory chip demand.

14. juuli 2026, 23:31 UTC

News
Social Media

Amazon.com Inc shares are higher in after-market trading amid positive sentiment. Analysts maintain a bullish outlook on the company's long-term investment strategy.

14. juuli 2026, 23:31 UTC

News

Netflix shares are higher in after-hours trading, buoyed by investor confidence despite rising subscription costs and regulatory scrutiny amid broader positive market sentiment.

14. juuli 2026, 23:31 UTC

News
Social Media

Alphabet Inc signed a fixed-price power purchase agreement for its largest solar-plus-storage project in the U.S. Shares are lower in after-market hours.

14. juuli 2026, 23:31 UTC

News
Correlated Moves

Apple Inc. shares were little changed after KeyBanc downgraded the rating to Sell with a price target of $250. OpenAI countered Apple's trade secret lawsuit claims.

14. juuli 2026, 23:11 UTC

News

The Australian Dollar is trading higher against the Singapore Dollar, supported by rising crude oil prices and improved U.S. inflation data.

14. juuli 2026, 23:06 UTC

News

Fiserv Inc. will release its second-quarter earnings on August 6, 2026, with shares trading higher in after-market hours amid positive sentiment.

14. juuli 2026, 23:06 UTC

News

Workday Inc. shares declined slightly in after-market trading following a challenging year, despite reporting 14.7% year-over-year growth in subscription revenue.

14. juuli 2026, 23:06 UTC

Macro News
News
Correlated Moves
ETF Constituents

Health Care Select Sector SPDR Fund is trading higher after proposed Medicare reforms by CMS and Anthem's new Alzheimer's testing coverage announcement.

14. juuli 2026, 23:06 UTC

News

United States Oil Fund LP trades higher in after-market hours as Iran withdraws from its agreement with the U.S., raising oil supply stability concerns.

14. juuli 2026, 23:01 UTC

News

Cintas Corp is higher in after-market trading, with its market capitalization surpassing Target Corp, positioning it 193rd in the S&P 500.

14. juuli 2026, 22:32 UTC

Correlated Moves
News

Geopolitical tensions and rising crude oil prices have contributed to an increase in CHF/HKD since Monday's close, reflecting broader market sentiment.

14. juuli 2026, 20:52 UTC

Correlated Moves
News

Vanguard Total Bond Market ETF advances in after-hours trading following a significant drop in the U.S. Consumer Price Index, easing inflation concerns and boosting Treasury demand.

14. juuli 2026, 20:07 UTC

News
Social Media

eBay shares are lower amid mixed analyst ratings and social media concerns about growth metrics. Jefferies raised the price target to $75 while maintaining an Underperform rating.

14. juuli 2026, 20:07 UTC

News

Xcel Energy shares are lower amid a settlement proposal for a $123 million revenue increase, with regulatory hearings scheduled for July 2026.

14. juuli 2026, 20:07 UTC

Social Media
Correlated Moves
News
Macro Event

Gold prices rose sharply today, with August futures reaching $4,092 an ounce after cooler CPI data. SPDR Gold Shares also benefited from this upward trend.

14. juuli 2026, 20:07 UTC

News
Social Media

Electronic Arts is set to launch EA Sports Madden NFL 27 Arcade Edition on August 6, contributing to positive investor sentiment as shares trade higher.

14. juuli 2026, 20:02 UTC

News
Macro Event

American Airlines shares are lower amid mixed options sentiment and elevated trading volume. The stock is set to report earnings on July 23.

14. juuli 2026, 20:02 UTC

Correlated Moves
News

Intuitive Surgical shares are lower as Baird cuts price target to $525 from $610. The stock has reached a 25-month low at $395.02.

14. juuli 2026, 20:02 UTC

News
Macro Event

Take-Two Interactive shares are trading lower amid recent inflation data, despite earlier gains during the session reflecting broader market pressures in the gaming sector.

14. juuli 2026, 19:56 UTC

News

Citigroup maintained its Buy rating on Monster Beverage and raised the price target to $113, contributing to a higher stock price since Monday's close.

14. juuli 2026, 19:52 UTC

Correlated Moves
ETF Constituents
News

Fitch affirmed Canada's credit rating at AA+, boosting sentiment for Canadian assets. The iShares MSCI Canada ETF is trading higher, supported by favorable USD/CAD movement.

14. juuli 2026, 19:52 UTC

Macro Event
News

NTAL launched to amplify daily participation in NTAP amid strong activity.

14. juuli 2026, 19:46 UTC

News

Marriott International shares rise amid positive sentiment from a new collaboration between The Ritz-Carlton and MERIT Beauty, with Macquarie raising its price target to $365.

14. juuli 2026, 19:45 UTC

News
Correlated Moves

Intuit Inc. shares are lower amid a class action lawsuit alleging securities fraud and an investigation into potential violations of federal securities laws.

14. juuli 2026, 19:41 UTC

Correlated Moves
Macro Event
News

U.S. CPI showed a month-over-month decrease, boosting demand for Treasury bonds. The iShares 20+ Year Treasury Bond ETF remains higher than Monday's close.

14. juuli 2026, 19:37 UTC

News
Social Media

KeyBanc maintains Overweight rating on Intel, raising price target to $155. Strong demand for AI-driven CPUs and improved yields support upward movement in shares today.

Võrdlus sarnastega

Hinnamuutus

Arcus Biosciences Inc Prognoos

Hinnasiht

By TipRanks

29.72% tõus

12 kuu keskmine prognoos

Keskmine 36.75 USD  29.72%

Kõrge 47 USD

Madal 22 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Arcus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

7

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

62 / 342 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat